Sciwind Closes $37 Million Round for Metabolic/Immunological Therapies

Hangzhou Sciwind closed a $37 Million series B financing led by LYFE Capital and joined by existing investors, Legend Capital and Haibang Venture Capital. Sciwind, known for its NASH projects, has started several clinical trials of candidates for metabolic and immunological diseases. It has completed a Phase I clinical study of a GLP-1 analogue weight loss treatment in Australia , and it plans to start China Phase II trials for therapies aimed at type II diabetes, obesity and non-alcoholic steatohepatitis (NASH). More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.